Objective: Nowadays Parkinson’s disease is one the problems of medicine which is waiting its solution.

Background: The aim of our study was to examine the effectiveness of the antidepressant Venlafaxine (venlafaxine hydrochloride) in PD patients with depressive disorders.

Method: We observed 35 patients with PD (16 men and 19 women) aged 49-76 years (mean age 61,6±8,7 years). Patients were evaluated on a Non-Motor Symptoms Scale for Parkinson’s Disease (NMSS), a questionnaire evaluating sleep quality (LSEG), Hamilton Depression Rating Scale (HAM-D). On NMSS scale results revealed the following violations: cardiology – in 18 patients (51.4%); sleep disturbance and fatigue in 20 (57.1%); cognitive and mental disorders in 15 (42.8%); memory and attention in 21 patients (61.0%); gastro-intestinal disorders observed in 19 patients (54.2%); genitourinary system – in 11 (31.4%).

Results: According to the results of the questionnaire assessing the quality of sleep was broken LSEG awakening during sleep, fall asleep, sleep quality in 22 patients (62.8%). According to the questionnaire HAM-D in 18 patients (51.4%) was identified depression: in 7 (38.9%) – mild (12-16 points), 11 (61.1%) – average (19- 21 points). To correct the depression was appointed antidepressant Venlafaxine (venlafaxine hydrochloride) 75 mg 1 hour before bedtime for 6 months follow-up. All patients received standard antiparkinsonian
therapy with levodopa. After a course taking Venlafaxine (venlafaxine hydrochloride) for data NMSS significant improvement was noted in 14 patients (77.7%). As a result of HAM-D scale of the average total score decreased in patients with mild depression to 4,6±1,2 points, with a mean depression to 6,3±2,2 points. Within one year of follow-up, patients treated with Venlafaxine, there was no need for a correction antiparkinsonian therapy.

Conclusion: 1. The use of Venlafaxine in PD reduces not only the symptoms of depression, but also some non-motor symptoms of the disease, which improves the quality of life of patients.
2. Venlafaxine helps restore the normal circadian rhythm of sleep-wake in patients with PD, 2.5-3 stage for Hyun-Yar.
3. The drug Venlafaxine in combination with standard antiparkinsonian therapyis well tolerated by patients with PD, 2.5-3 stage for Hyun-Yar, depression of mild to moderate severity.

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/clinical-features-of-depressive-disorders-in-parkinsons-disease-possibilities-of-their-correction/